UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): August 27, 2024
Elicio Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
001-39990
|
|
11-3430072
|
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
451 D Street, 5th Floor
Boston, Massachusetts 02210
(Address of principal executive offices and Zip Code)
(857) 209-0050
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2 below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.01 par value per share
|
|
ELTX
|
|
The Nasdaq Global Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any
new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On August 27, 2024, Brian Piekos, the Chief Financial Officer and Treasurer of Elicio Therapeutics, Inc. (the “Company”), informed
the Company of his intent to resign from his positions, effective September 6, 2024, to pursue another opportunity. Mr. Piekos’ resignation is not the result of any disagreement with the Company on any matter related to the Company's financial
reporting or accounting policies, procedures, estimates or judgments. The Company thanks Mr. Piekos for his service and wishes him well. The Company has initiated a search for a new Chief Financial Officer.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
| |
|
Elicio Therapeutics, Inc.
|
| |
|
|
|
Date:
|
August 30, 2024
|
By:
|
/s/ Robert Connelly
|
| |
|
Name:
|
Robert Connelly
|
| |
|
Title:
|
President and Chief Executive Officer
(Principal Executive Officer)
|